A demonstration about integrating GLP-1 Inhibitors into diabetes care management from the 2015 National Medical Association Scientific Assembly, Family Medicine Section held August 3rd in Detroit, Michigan.
From the Psychiatry and Behavioral Health Section held August 4, 2016 at the 113th NMA Annual Convention and Scientific Assembly in Detroit, MI
Pulmonary arterial hypertension encompasses associated forms of the disease, induced by secondary disease states which cause stress and injury to the pulmonary vascular bed potentiating progressive pulmonary vasculopathy.
A continuing discussion about integrating GLP-1 Inhibitors into diabetes care management from the 2015 National Medical Association Scientific Assembly, Family Medicine Section held August 3rd in Detroit, Michigan.
New guidelines presented on diagnosis, treatment and medications across mental and medical therapeutic areas.
Dr. Kwame Osei discusses the pathophysiology and demographics of type 2 diabetes patients, and how best to treat these patients.
Dr. James Gavin presents the impact of SGLT2 inhibitors on patients with type 2 diabetes.
Dr. Anthony J. Cannon examines the DPP IV pharmacologic classes of anitdiabetic agents and looks at its ability to lower A1C values in addition to measuring their effects on hypoglycemic potential, weight and overall safety profile.
Dr. Ayotunde Dokun examines the different types of agents used in managing weight loss in patients with diabetes.
Presented by Kelvin J. Holloway, MD, MBA
Presented by Joseph A. Tyndall, MD, MPH, FACEP
Presented by Dr. Cynthia Price
Presented by Melody Carter, MD
Presented by Charles Gbadouwey, MD, FCCP
Presented by Presented by Margaret McDonlad, MSW
Presented by Valory N. Pavlik, PhD
Presented by David Hyman, MD
Presented by Jerome A. Robinson, MD at the 112th Annual NMA Convention and Scientific Assembly
Presented by Anthony J. Cannon, MD